Cargando…

Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia

HPV immunization programs are mainly focused on girls and boys, but adult women and men could also benefit from vaccination. A multinational CoheaHr-WP4 study investigated the acceptability of HPV vaccination among 25–45 years old women. A total of 607 women from Slovenia participated in the study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mlakar, Jana, Oštrbenk Valenčak, Anja, Kežar, Jožefa, Beseničar-Pregelj, Lara, Poljak, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964155/
https://www.ncbi.nlm.nih.gov/pubmed/36851300
http://dx.doi.org/10.3390/vaccines11020423
_version_ 1784896432638001152
author Mlakar, Jana
Oštrbenk Valenčak, Anja
Kežar, Jožefa
Beseničar-Pregelj, Lara
Poljak, Mario
author_facet Mlakar, Jana
Oštrbenk Valenčak, Anja
Kežar, Jožefa
Beseničar-Pregelj, Lara
Poljak, Mario
author_sort Mlakar, Jana
collection PubMed
description HPV immunization programs are mainly focused on girls and boys, but adult women and men could also benefit from vaccination. A multinational CoheaHr-WP4 study investigated the acceptability of HPV vaccination among 25–45 years old women. A total of 607 women from Slovenia participated in the study, and 49.6% (301/607) agreed with HPV vaccination, with a significant difference (p < 0.0001) between the two centers. Non-vaccinated women had a higher education (p = 0.0068) and were more frequently in a committed relationship or married (p = 0.01). The most trusted source of medical and vaccination information was healthcare providers (55.2%). The main reasons for vaccine acceptance were protection against HPV-related disease (93.4%), severity of preventable diseases (82.7%), HPV vaccine safety (66.8%), free HPV vaccine availability (62.8%), and the existence of vaccination recommendations (55.5%). The main reasons for refusing vaccination were the need for additional vaccine-related information (31.4%) and vaccine safety concerns (29.4%). To increase vaccine coverage, information about the benefits and safety of HPV vaccination must be widely disseminated to all health professionals and the general public. We are convinced that the knowledge obtained in this study can be reliably applied to other countries in the region that lack such information and have a very high cervical cancer burden.
format Online
Article
Text
id pubmed-9964155
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99641552023-02-26 Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia Mlakar, Jana Oštrbenk Valenčak, Anja Kežar, Jožefa Beseničar-Pregelj, Lara Poljak, Mario Vaccines (Basel) Article HPV immunization programs are mainly focused on girls and boys, but adult women and men could also benefit from vaccination. A multinational CoheaHr-WP4 study investigated the acceptability of HPV vaccination among 25–45 years old women. A total of 607 women from Slovenia participated in the study, and 49.6% (301/607) agreed with HPV vaccination, with a significant difference (p < 0.0001) between the two centers. Non-vaccinated women had a higher education (p = 0.0068) and were more frequently in a committed relationship or married (p = 0.01). The most trusted source of medical and vaccination information was healthcare providers (55.2%). The main reasons for vaccine acceptance were protection against HPV-related disease (93.4%), severity of preventable diseases (82.7%), HPV vaccine safety (66.8%), free HPV vaccine availability (62.8%), and the existence of vaccination recommendations (55.5%). The main reasons for refusing vaccination were the need for additional vaccine-related information (31.4%) and vaccine safety concerns (29.4%). To increase vaccine coverage, information about the benefits and safety of HPV vaccination must be widely disseminated to all health professionals and the general public. We are convinced that the knowledge obtained in this study can be reliably applied to other countries in the region that lack such information and have a very high cervical cancer burden. MDPI 2023-02-12 /pmc/articles/PMC9964155/ /pubmed/36851300 http://dx.doi.org/10.3390/vaccines11020423 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mlakar, Jana
Oštrbenk Valenčak, Anja
Kežar, Jožefa
Beseničar-Pregelj, Lara
Poljak, Mario
Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia
title Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia
title_full Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia
title_fullStr Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia
title_full_unstemmed Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia
title_short Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia
title_sort assessment of acceptability and determinants of uptake and schedule completion of human papillomavirus (hpv) vaccine by 25 to 45 years old women in slovenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964155/
https://www.ncbi.nlm.nih.gov/pubmed/36851300
http://dx.doi.org/10.3390/vaccines11020423
work_keys_str_mv AT mlakarjana assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia
AT ostrbenkvalencakanja assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia
AT kezarjozefa assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia
AT besenicarpregeljlara assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia
AT poljakmario assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia